Information Provided By:
Fly News Breaks for February 21, 2020
EDIT
Feb 21, 2020 | 06:23 EDT
Wells Fargo analyst Yanan Zhu initiated coverage of Editas Medicine with an Equal Weight rating and $28 price target. While Editas has the industry's most advanced Crisper genome editing platform and a highly competitive sickle cell disease program, there is "potentially under-appreciated technical risk" to its lead clinical program targeting Leber Congenital Amaurosis-10 and extended timelines to data from the sickle cell program, Zhu tells investors in a research note. As such, the analyst sees the stock as fairly valued.
News For EDIT From the Last 2 Days
There are no results for your query EDIT
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.